EML4‐ALK G1202R and EML4‐ALK L1196M mutations induce crizotinib resistance in non‐small cell lung cancer cells through activating epithelial–mesenchymal transition mediated by MDM2/MEK/ERK signal axis
Cell Biology International · 2025
DOI: 10.1002/cbin.12249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology International, 2025. Verfasst von Yuying Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Crizotinib, Epithelial-Mesenchymal Transition, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins c-mdm2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: The Innovative Talents Support Plan of Colleges and Universities in Liaoning Province.
Abstract (Originalsprache)
Crizotinib, as the first‐generation of anaplastic lymphoma kinase (ALK) inhibitor, effectively improves the survival time of ALK‐positive non‐small cell lung cancer (NSCLC) patients. However, its efficacy is severely limited by drug resistance caused by secondary mutations. G1202R and L1196M are classical mutation sites located in ALK kinase domain. They may hinder the binding of ALK inhibitors to the target kinase domain, resulting in drug resistance in patients. However, the exact mechanism of drug resistance mediated by these mutations remains unclear. In this study, we aimed to evaluate how G1202R and L1196M mutations mediate crizotinib resistance. To explore the resistance mechanism, we constructed EML4‐ALK G1202R and L1196M mutant cell lines with A549 cells. The results showed that the mutant cells exhibited significant epithelial–mesenchymal transition (EMT) and metastasis compared to control (A549‐vector) or wild type (A549‐EML4‐ALK) cells. Subsequently, it was found that the occurrence of EMT was correlated to the high expression of murine double minute 2 (MDM2) protein and the activation of mitogen‐activated protein kinase (MEK)/extracellular signal‐regulated kinase (ERK) pathway in mutant cells. Down‐regulation of MDM2 inhibited the activation of MEK/ERK pathway, thus reversed the EMT process and markedly increased the inhibitory effect of crizotinib on the growth of mutant cells. Collectively, resistance of ALK‐positive NSCLC cells to crizotinib is induced by G1202R and L1196M mutations through activation of the MDM2/MEK/ERK signalling axis, promoting EMT process and metastasis. These findings suggest that the combination of MDM2 inhibitors and crizotinib could be a potential therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
Förderung
- The Innovative Talents Support Plan of Colleges and Universities in Liaoning Province
Zitieren
APA
Yang, Y., Yang, H., Gao, Y., Yang, Q., Zhu, X., Miao, Q., Xu, X., Li, Z., & Zuo, D. (2025). EML4‐ALK G1202R and EML4‐ALK L1196M mutations induce crizotinib resistance in non‐small cell lung cancer cells through activating epithelial–mesenchymal transition mediated by MDM2/MEK/ERK signal axis. Cell Biology International. https://doi.org/10.1002/cbin.12249
Vancouver
Yang Y, Yang H, Gao Y, Yang Q, Zhu X, Miao Q, et al. EML4‐ALK G1202R and EML4‐ALK L1196M mutations induce crizotinib resistance in non‐small cell lung cancer cells through activating epithelial–mesenchymal transition mediated by MDM2/MEK/ERK signal axis. Cell Biology International. 2025. doi:10.1002/cbin.12249
BibTeX
@article{Yang2025,
author = {Yang, Yuying and Yang, Huan and Gao, Yunhui and Yang, Qian and Zhu, Xinya and Miao, Qianying and Xu, Xiaobo and Li, Zengqiang and Zuo, Daiying},
title = {EML4‐ALK G1202R and EML4‐ALK L1196M mutations induce crizotinib resistance in non‐small cell lung cancer cells through activating epithelial–mesenchymal transition mediated by MDM2/MEK/ERK signal axis},
journal = {Cell Biology International},
year = {2025},
doi = {10.1002/cbin.12249}
}
EUVIMED